Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Geron Corporation

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Axsome Therapeutics, Inc. and Geron Corporation have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

Axsome Therapeutics, Inc.

From 2014 to 2023, Axsome Therapeutics increased its R&D expenses by over 2,000%, peaking in 2023 with a remarkable $97.9 million. This surge underscores their aggressive pursuit of novel therapies, particularly in the fields of neuroscience and pain management.

Geron Corporation

Similarly, Geron Corporation's R&D spending grew by approximately 500% during the same period, reaching $125 million in 2023. This growth highlights their focus on pioneering treatments in oncology, particularly in telomerase inhibition.

Both companies exemplify the biotech sector's relentless drive towards innovation, with R&D investments reflecting their strategic priorities and potential for future breakthroughs.